Table 1.
Baseline demographics and characteristics of evaluable patients
| Characteristic | Vorinostat-EPOCH +/−R (n = 44) | EPOCH +/−R (n = 42) | All patients (N = 86) | P* | ||
|---|---|---|---|---|---|---|
| n (%) | Median (range) | n (%) | Median (range) | Total (%) | ||
| Sex | .056 | |||||
| Female | 5 (11) | 0 | 5 (6) | |||
| Male | 39 (89) | 42 (100) | 81 (94) | |||
| Race/ethnicity | .87 | |||||
| White/non-Hispanic | 16 (36) | 20 (48) | 36 (42) | |||
| White/Hispanic | 7 (16) | 8 (19) | 15 (17) | |||
| Other Hispanic | 6 (14) | 4 (10) | 10 (12) | |||
| African American | 12 (27) | 8 (19) | 20 (23) | |||
| Asian | 1 (2) | 1 (2) | 2 (2) | |||
| Unknown | 2 (5) | 1 (2) | 3 (3) | |||
| Age, y | 50 (26-70) | 46 (24-66) | .048 | |||
| CDC risk factors | ||||||
| Homosexual/bisexual contact | 18 (43) | 26 (62) | 44 (52) | .13 | ||
| Heterosexual contact | 22 (51) | 10 (24) | 32 (38) | .014 | ||
| IV drug use | 2 (5) | 4 (10) | 6 (7) | .43 | ||
| Transfusion recipient | 1 (2) | 2 (5) | 3 (4) | .62 | ||
| Other CDC risk factor | 2 (5) | 3 (7) | 5 (6) | .68 | ||
| More than 1 risk factor | 4 (9) | 4 (9) | 8 (9) | .99 | ||
| ART use (at baseline) | .27 | |||||
| Yes | 38 (86) | 40 (95) | — | |||
| No | 6 (14) | 2 (5) | — | |||
| Absolute CD4 count (cells/mm3) | ||||||
| Numeric values | 186 (63-1 137) | 195 (50-1 061) | .84 | |||
| <100 | 5 (11) | 6 (14) | 11 (13) | .87 | ||
| 100-200 | 19 (43) | 16 (38) | 35 (41) | |||
| >200 | 20 (45) | 20 (47) | 40 (46) | |||
| HIV VL (copies/mL) | ||||||
| Positive and above limit | 25 (57) | 27 (64) | 52 (60) | .51 | ||
| Undetected or below limit | 19 (43) | 15 (36) | 34 (40) | |||
| Values that were positive and above limit | 17 100 (36-1 712 000) | 934 (2-901 000) | .32 | |||
| Ann Arbor stage | .99 | |||||
| I-II | 8 (18) | 7 (17) | 15 (17) | |||
| III-IV | 36 (82) | 35 (83) | 71 (83) | |||
| aa-IPI risk | .65 | |||||
| 0-1 | 16 (36) | 13 (31) | 29 (34) | |||
| 2-3 | 28 (64) | 29 (69) | 57 (66) | |||
| LDH elevation | .81 | |||||
| Yes | 34 (77) | 30 (71) | 64 (74) | |||
| No | 10 (23) | 12 (29) | 32 (26) | |||
| Ki-67 expression | .08 | |||||
| ≥80% | 31 (70) | 37 (88) | 68 (79) | |||
| <80% | 6 (14) | 4 (10) | 10 (12) | |||
| Inconclusive or ND | 7 (16) | 1 (2) | 8 (9) | |||
| Pathologic diagnosis | .79 | |||||
| DLBCL | 30 (68) | 31 (73) | 61 (71) | |||
| PBL | 8 (18) | 7 (17) | 15 (17) | |||
| PEL | 5 (11) | 2 (5) | 7 (8) | |||
| BCL-U | 1 (2) | 1 (2) | 2 (2) | |||
| BL | 0 (0) | 1 (2) | 1 (1) | |||
| Prior chemotherapy | .51 | |||||
| 1 cycle | 16 (36) | 19 (45) | 35 (41) | |||
| None | 28 (64) | 23 (55) | 51 (59) | |||
| DTI | .39 | |||||
| <15 d | 25 (57) | 19 (45) | 44 (51) | |||
| 15 d | 19 (43) | 23 (55) | 42 (49) | |||
BCL-U, B-cell lymphoma, unclassifiable, with features between DLBCL and BL; LDH, lactate dehydrogenase.
*
P-values are from Wilcoxon rank-sum tests, on age, absolute CD4 counts, and HIV VL, and from Fisher’s exact test on all other patient characteristics. All P-values are 2-sided.